Literature DB >> 11555569

Is circulating HER-2 more than just a tumor marker?

J Baselga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11555569

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  8 in total

1.  Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens.

Authors:  R Nahta; S Shabaya; T Ozbay; D L Rowe
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-12-01

2.  Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer.

Authors:  Sun-Young Kong; Do Hoon Lee; Eun Sook Lee; Susan Park; Keun Seok Lee; Jungsil Ro
Journal:  Cancer Res Treat       Date:  2006-02-28       Impact factor: 4.679

3.  Evaluation of immunohistochemistry and enzyme linked immunosorbent assay for HER-2/neu expression in breast carcinoma.

Authors:  Rani James; K Thriveni; Girija Ramaswamy; Lakshmi Krishnamoorthy; Geetashree Mukherjee; P P Vijayalaxmi Deshmane; P P Bapsy
Journal:  Indian J Clin Biochem       Date:  2008-12-20

4.  Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.

Authors:  I Witzel; S Loibl; G von Minckwitz; H Eidtmann; T Fehm; F Khandan; S Schmatloch; M Hauschild; J Bischoff; P A Fasching; C Mau; C Schem; B Rack; I Meinhold-Heerlein; C Liedtke; T Karn; J Huober; C Zu Eulenburg; Y Issa-Nummer; M Untch; V Müller
Journal:  Br J Cancer       Date:  2012-08-14       Impact factor: 7.640

5.  Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

Authors:  Francisco J Esteva; Carol D Cheli; Herbert Fritsche; Monica Fornier; Dennis Slamon; Robert P Thiel; Diana Luftner; Farooq Ghani
Journal:  Breast Cancer Res       Date:  2005-04-08       Impact factor: 6.466

6.  The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients.

Authors:  Moo Hyun Lee; So-Youn Jung; Sun Hee Kang; Eun Jin Song; In Hae Park; Sun-Young Kong; Young Mee Kwon; Keun Seok Lee; Han-Sung Kang; Eun Sook Lee
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

7.  Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.

Authors:  Tanja Fehm; Sven Becker; Silke Duerr-Stoerzer; Karl Sotlar; Volkmar Mueller; Diethelm Wallwiener; Nancy Lane; Erich Solomayer; Jonathan Uhr
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

8.  Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis.

Authors:  Amir Shamshirian; Amir Reza Aref; George W Yip; Majid Ebrahimi Warkiani; Keyvan Heydari; Sajad Razavi Bazaz; Zeinab Hamzehgardeshi; Danial Shamshirian; Mahmood Moosazadeh; Reza Alizadeh-Navaei
Journal:  BMC Cancer       Date:  2020-10-31       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.